Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.
Fang FangXiao-Xi LanRong-Hua HuWu-Han HuiHong ZhaoYi-Xian GuoBing-Xin JiHong-Jun LiuLi SuWan-Ling SunPublished in: Therapeutic advances in neurological disorders (2024)
Bortezomib was well-tolerated by patients with POEMS syndrome. Compared with CD ± T regimen, BCD as the induction regimen achieved better VEGF response and earlier hematological remission. Autologous stem cell transplantation used as consolidation therapy further improved the neurological and hematological remission rates, resulting in better OS and PFS.
Keyphrases
- newly diagnosed
- stem cell transplantation
- high dose
- low dose
- end stage renal disease
- multiple myeloma
- case report
- disease activity
- chronic kidney disease
- endothelial cells
- ejection fraction
- ulcerative colitis
- peritoneal dialysis
- cell therapy
- rheumatoid arthritis
- bone marrow
- mesenchymal stem cells
- systemic lupus erythematosus
- vascular endothelial growth factor
- stem cells
- patient reported
- replacement therapy